This is a routine pipeline update with no new financial data. The presentation reiterates known Phase 2a data and upcoming milestones. Monitor for EVO756 Phase 2b migraine top-line data in 2027 and EVO301 Phase 2b initiation in mid-2027 as key catalysts.
Price Chart
Executive Summary
Evommune posted an updated corporate presentation on its website via an 8-K (Item 7.01). The presentation highlights Phase 2a proof-of-concept data for EVO301 (IL-18BP) in atopic dermatitis, showing a 34% placebo-adjusted EASI improvement at week 8, and outlines upcoming catalysts: Phase 2b data for EVO756 in migraine (2027), Phase 2b initiation for EVO301 in mid-2027, and Phase 1 entry for EVO646 in 1H2027. The company reports ~$287M cash and investments with runway into 2029. This is a routine pipeline update with no new financial data or material changes in fundamentals.
Key Facts
- Evommune posted an updated corporate presentation on its website.
- EVO301 Phase 2a in AD showed 34% placebo-adjusted EASI improvement at week 8.
- 23% of EVO301 patients achieved IGA 0/1 at week 12 vs 0% on placebo.
- EVO756 Phase 2b migraine trial top-line data expected in 2027.
- EVO301 Phase 2b in AD expected to initiate mid-2027.
- EVO646 (TLR7/8 antagonist) plan to enter Phase 1 in 1H 2027.
- Company reports ~$287M cash and investments with expected runway into 2029.
Financial Impact
No new financial data reported. Company disclosed ~$287M cash and investments with runway into 2029.
Risk Factors
- Clinical trial failure for EVO756, EVO301, or EVO646
- Competitive pressure from existing AD biologics (Dupixent, Ebglyss, Nemluvio) and migraine therapies (CGRPs)
- Cash runway depends on no unexpected delays or cost overruns
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-391390 |
| Document: evmn-ex99_1.htm | 0001193125-26-391390 |
| Document: 0001193125-26-391390-index-headers.html | 0001193125-26-391390 |
| Document: 0001193125-26-391390-index.html | 0001193125-26-391390 |
| Document: 0001193125-26-391390.txt | 0001193125-26-391390 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | 8-K | $7.21 | awaiting T+60 | — | $5.16 (−28.43%) |
Sep 15, 2026 6w ago | 8-K | $9.99 | awaiting T+60 | — | $5.16 (−48.35%) |
Jul 30, 2026 12w ago | 8-K | $11.35 $5.10 | ▼ −55.07% | ▼ −57.53% | $5.16 (−54.54%) |
Jul 10, 2026 15w ago | Insider Cluster | $12.10 $6.61 | ▼ −45.37% | ▼ −49.37% | $5.16 (−57.36%) |
Jun 29, 2026 17w ago | 8-K | $15.05 $9.60 | ▲ +36.21% | ▲ +40.60% | $5.16 (+65.71%) |
Jun 24, 2026 17w ago | Insider Cluster | $24.13 $9.65 | ▼ −60.01% | ▼ −63.74% | $5.16 (−78.62%) |
Jun 3, 2026 20w ago | Insider Cluster | $20.69 $13.23 | ▲ +36.06% | ▲ +37.94% | $5.16 (+75.06%) |
Jun 2, 2026 21w ago | 144 | $19.73 $13.48 | ▼ −31.68% | ▼ −34.18% | $5.16 (−73.85%) |
Jun 1, 2026 21w ago | Insider Cluster | $19.82 $14.11 | ▼ −28.81% | ▼ −29.93% | $5.16 (−73.97%) |
May 28, 2026 21w ago | 144 | $23.23 $13.67 | ▲ +41.15% | ▲ +42.34% | $5.16 (+77.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers